Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 8/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PDE1A | P54750 | 1/20 | 0.45 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.45 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL587425 | 0.89 | PDE4B (0.60) | PDE4BGAAMAPTSMN1; SMN2ADORA1 | |
| SCHEMBL11799124 | 0.87 | PDE4B (0.52) | PDE4BMAPTSMN1; SMN2ADORA1LMNA | |
| SCHEMBL2792459 | 0.87 | ALDH1A1 (0.49) | PDE4BGAAMAPTSMN1; SMN2ADORA1 | |
| SCHEMBL30644829 | 0.87 | ALDH1A1 (0.49) | PDE4BGAAMAPTSMN1; SMN2ADORA1 | |
| SCHEMBL12604334 | 0.82 | UCHL1 (0.51) | PDE4BGAAMAPTSMN1; SMN2UCHL1 | |
| SCHEMBL14565693 | 0.82 | ALDH1A1 (0.50) | PDE4BMAPTSMN1; SMN2ADORA1LMNA | |
| SCHEMBL583328 | 0.82 | GAA (0.74) | PDE4BGAAMAPTSMN1; SMN2ADORA1 | |
| SCHEMBL7012617 | 0.81 | PDE4B (0.67) | PDE4BMAPTNPC1ALDH1A1PDE5A | |
| SCHEMBL20745892 | 0.81 | NPC1 (0.59) | PDE4BGAAMAPTSMN1; SMN2ADORA1 | |
| SCHEMBL583379 | 0.80 | PDE4B (0.74) | PDE4BGAAADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113698395-B | Transforming growth factor receptor antagonist, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4186897-A1 | PYRIDINECARBOXAMIDE COMPOUND USEFUL AS PIM KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-4186897-A1 | PYRIDINECARBOXAMIDE COMPOUND USEFUL AS PIM KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-3670506-B1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-3670506-B1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| US-11485745-B2 | Amido spirocyclic amide and sulfonamide derivatives | VALO HEALTH, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2022-01-25 | — | — | US | disclosed |
| CN-113698395-A | Transforming growth factor receptor antagonist, preparation method and application thereof | 成都倍特药业股份有限公司 | 2021-11-26 | — | — | CN | disclosed |
| US-20210171545-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | VALO HEALTH, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20200405702-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2020-12-31 | — | — | US | disclosed |
| EP-1921078-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-14 | — | — | EP | disclosed |
| EP-1921078-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007134259-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-11-22 | — | — | WO | disclosed |
| EP-1043998-B1 | USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDANT KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-03-07 | — | — | EP | disclosed |
| EP-1278749-B1 | USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1278749-A1 | USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-01-29 | — | — | EP | disclosed |
| US-6448264-B2 | ANTIPROLIFERATIVE, -CARCINOGENIC AGENTS, ANTIINFLAMMATORY AND -ARTHRITIS AGENTS; NEURODEGENERATIVE DISEASES, E.G., ALZHEIMER'S DISEASE; CARDIOVASCULAR DISORDERS; VIRICIDES; FUNGICIDES | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-10 | — | — | US | disclosed |
| US-20020002178-A1 | Use of 5-thio-, sulfinyl- and sulfonylpyrazolo[3,4-b]- pyridines as cyclin dependent kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-01-03 | — | — | US | disclosed |
| WO-2001081348-A1 | USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO[3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
| US-6107305-A | Use of pyrazolo [3,4-b] pyridine as cyclin dependent kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002178-A1 | Use of 5-thio-, sulfinyl- and sulfonylpyrazolo[3,4-b]- pyridines as cyclin dependent kinase inhibitors | CCNI, CDK2, CDK1 | PDE4B 2510/4885GAA 4341/4885MAPT 1537/4885 |
| US-20210171545-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | STS, AADAC, SULT2A1 | PDE4B 1995/4885GAA 1153/4885MAPT 2267/4885 |
| US-11485745-B2 | Amido spirocyclic amide and sulfonamide derivatives | STS, AADAC, SULT2A1 | PDE4B 1995/4885GAA 1153/4885MAPT 2267/4885 |
| US-20200405702-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM2, PIM1, PIM3 | PDE4B 2980/4885GAA 1208/4885MAPT 3436/4885 |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | PIM2, PIM1, PIM3 | PDE4B 2980/4885GAA 1208/4885MAPT 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.